Authors
Ernesto Margarita, Kosei Saito, Piergiorgio Bisegna, Margherita Ferrari, Eleonora Valeriani, Marzia Guerrieri, Barbara Funaro, Daniela Feliciani, Antonio Gasbarrini, Serena Porcari, Gianluca Ianiro
Published in
Best practice & research. Clinical gastroenterology. Volume 83. Pages 102143. Epub Sep 24, 2026.
Abstract
Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape of multiple malignancies, yet durable clinical benefit remains limited to a subset of patients, while immune-related adverse events still represent a major therapeutic challenge. Over the past decade, compelling evidence has established the gut microbiota as a key host determinant of both the efficacy and toxicity of cancer immunotherapy. Given its profound diversity and plasticity, as well as its impact on systemic immunity, gut commensals are now considered as both a promising predictive biomarker of response and a potentially actionable therapeutic target. As a result, different microbiota-informed approaches are being explored for precision immune-oncology. Specifically, emerging biomarker strategies are moving beyond single bacterial taxa toward ecological and functional microbial signatures with improved reproducibility across patient cohorts. At the same time, therapeutic modulation of the gut microbiome, through dietary interventions, prebiotics, probiotics, and fecal microbiota transplantation, is being actively investigated to enhance responsiveness to ICIs and mitigate immune-related adverse events. In this review, we discuss the biological mechanisms linking gut microbiota and immunotherapy, evaluate its role as biomarker and therapeutic target, and address the current challenges that need to be overcome to integrate microbiota into precision immune-oncology.
PMID:
42971669
Bibliographic data and abstract were imported from PubMed on 03 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 11
- Comments 0